Binimetinib/Encorafenib Combo Approved in Europe for BRAF+ Melanoma

September 20, 2018 – The European Commission has approved the combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib for the treatment of adult patients with BRAF V600–mutant unresectable or metastatic melanoma, according to Array BioPharma, the company developing the regimen. The approval is based on the phase III COLUMBUS trial, in which at a median follow-up of 36.8 months, combining encorafenib at 450 mg daily and … (leggi tutto)